James Hippel, Chief Financial Officer of BIO-TECHNE Corp (NASDAQ:TECH), filed a Form 4 on November 3, 2026, disclosing transactions in common stock and derivative securities dated November 1, 2026.

Key Highlights

  • RSU vesting: 11,545 restricted stock units converted to common stock on November 1, 2026, at a price of $0 (transaction code M).
  • Tax withholding disposition: 5,096 shares were disposed of on November 1, 2026, at $72.66 per share (transaction code F).
  • Resulting direct ownership: Following the transactions, Hippel directly held 176,720 shares of common stock.
  • Derivative holdings: Hippel holds stock options across seven tranches with exercise prices ranging from $53.60 to $120.46, plus multiple RSU and performance RSU awards covering thousands of additional underlying shares.
  • Remaining RSUs from same grant: 11,544 restricted stock units from the same series are scheduled to vest on November 1, 2027, according to the filing.
  • Filing signed by attorney-in-fact: The form was signed by Andrew Nick as attorney-in-fact for James Hippel pursuant to a previously filed power of attorney.

James Hippel's November 2026 RSU Vest and Share Disposition at BIO-TECHNE

According to the Form 4 filed with the SEC on November 3, 2026, BIO-TECHNE Corp CFO James Hippel reported two transactions in common stock on November 1, 2026. First, 11,545 restricted stock units vested and were acquired as common stock at a price of $0 (transaction code M), bringing his total direct beneficial ownership to 181,816 shares before any further adjustment. Second, 5,096 shares were disposed of at $72.66 per share (transaction code F), leaving Hippel with a direct holding of 176,720 shares of common stock.

The filing discloses that the vesting relates to a restricted stock unit grant under which 11,545 units were scheduled to vest on November 1, 2026, and 11,544 units remain scheduled to vest on November 1, 2027. Each restricted stock unit represents, as the filing states, "a contingent right to receive one share of Bio-Techne Corporation common stock."

In addition to common stock holdings, the filing reports that Hippel holds stock options with exercise prices of $66.97, $120.46, $94.52, $84.61 (two separate tranches), $74.91, and $53.60, with expiration dates ranging from August 5, 2027, through August 15, 2035. He also holds multiple performance restricted stock unit awards and additional restricted stock unit awards with vesting schedules extending through August 17, 2029, all held directly.

What Was Disclosed

BIO-TECHNE CFO James Hippel disclosed the vesting of 11,545 RSUs and the disposition of 5,096 shares on November 1, 2026, resulting in a direct beneficial ownership of 176,720 shares of common stock, along with extensive derivative security holdings.